Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer
The aim of this study is to explore whether FOLFOX6 as treatment could improve the time to progression (TTP) and overall survival (OS) of the patient with recurrent or metastatic esophagus.
Esophageal Squamous Cell Carcinoma
DRUG: FOLFOX6
TPP, from the first cycle of treatment (day one) to two month after the last cycle
OS, from the first cycle of treatment (day one) to two month after the last cycle
Explore whether FOLFOX6 as treatment could improve the TTP and OS of the patient with recurrent or metastatic esophagus